Fig. 3From: Therapeutic benefits of recombinant alpha1-antitrypsin IgG1 Fc-fusion protein in experimental emphysemaExperimental protocol to assess the effects of AAT-Fc following cigarette smoke exposure (A). During the last 3 months of 6-month long CS exposure, mice received AAT-Fc, pAAT, IgG1-Fc, or PBS as a vehicle control every 10 days (Cs AAT-Fc, CS pAAT, CS IgG1-Fc, or CS vehicle, respectively). A control group of mice were exposed to ambient air (Air). Cst values (B), lung tissue sections (C), MLI (D), and alveolar surface area (S) (E) values were compared between each group of mice. n = 8 in each group. *p < 0.05 by Tukey–Kramer testBack to article page